PT1194167E - Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b - Google Patents

Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b Download PDF

Info

Publication number
PT1194167E
PT1194167E PT00941278T PT00941278T PT1194167E PT 1194167 E PT1194167 E PT 1194167E PT 00941278 T PT00941278 T PT 00941278T PT 00941278 T PT00941278 T PT 00941278T PT 1194167 E PT1194167 E PT 1194167E
Authority
PT
Portugal
Prior art keywords
antibodies
autoimmune disorders
immunotherapy
cells
target
Prior art date
Application number
PT00941278T
Other languages
English (en)
Portuguese (pt)
Inventor
David M Goldenberg
Hans J Hansen
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of PT1194167E publication Critical patent/PT1194167E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
PT00941278T 1999-06-09 2000-06-09 Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b PT1194167E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13828499P 1999-06-09 1999-06-09

Publications (1)

Publication Number Publication Date
PT1194167E true PT1194167E (pt) 2009-10-23

Family

ID=22481331

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00941278T PT1194167E (pt) 1999-06-09 2000-06-09 Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b

Country Status (14)

Country Link
US (10) US7074403B1 (enExample)
EP (2) EP1194167B1 (enExample)
JP (1) JP4286483B2 (enExample)
KR (1) KR20020020730A (enExample)
AT (1) ATE439860T1 (enExample)
AU (4) AU782160B2 (enExample)
CA (1) CA2375912C (enExample)
CY (1) CY1110556T1 (enExample)
DE (2) DE60042785D1 (enExample)
DK (1) DK1194167T3 (enExample)
ES (1) ES2331644T3 (enExample)
HK (1) HK1046635B (enExample)
PT (1) PT1194167E (enExample)
WO (1) WO2000074718A1 (enExample)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
ATE311199T1 (de) * 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU778863B2 (en) * 1999-07-12 2004-12-23 Genentech Inc. Blocking immune response to a foreign antigen using an antagonist which binds to CD20
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1383919B1 (en) * 2001-03-29 2010-07-07 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
HU228957B1 (en) * 2001-07-02 2013-07-29 Aimsco Ltd Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
WO2003064472A2 (en) * 2002-01-28 2003-08-07 Aimsco Limited Treatment of ms with goat serum
CA2453995A1 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
RU2004127458A (ru) * 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Анти-cd20 антитела, их гибридные белки и способы их использования
DE60334364D1 (de) * 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
AU2015201433B2 (en) * 2002-03-01 2017-01-12 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
JP4472351B2 (ja) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗ｃｄ７４抗体およびその使用方法
AU2012216518B2 (en) * 2002-03-01 2014-12-18 Immunomedics, Inc. Internalizing Anti-CD74 Antibodies and Methods of Use
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
AU2015246156B2 (en) * 2002-05-02 2017-06-29 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
US20050043516A1 (en) * 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
EP1944320A1 (en) * 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
AU2011236095B2 (en) * 2003-01-24 2013-08-01 Immunomedics, Inc. Anthracycline-antibody conjugates
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
SI1613350T1 (sl) 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PT2272868E (pt) * 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
BRPI0412629A (pt) * 2003-08-29 2006-09-26 Genentech Inc método de tratamento de disfunção ocular em mamìferos
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
KR20060107555A (ko) * 2003-12-19 2006-10-13 제넨테크, 인크. 이식 거부에서 ｃｄ20의 검출
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
EP1773393A2 (en) * 2004-05-05 2007-04-18 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
CA2568336A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
JP2008507555A (ja) * 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド シェーグレン症候群の治療方法
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
RU2411956C2 (ru) * 2004-10-05 2011-02-20 Дженентек, Инк. Способ лечения васкулита
SV2006002258A (es) * 2004-10-08 2006-09-19 Wyeth Corp Inmunoterapia de trastornos autoinmunes
GT200600020A (es) * 2005-01-13 2006-11-08 Procedimiento de tratamiento
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
HUE025945T2 (en) * 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
ES2829566T3 (es) 2005-03-03 2021-06-01 Immunomedics Inc Anticuerpos L243 humanizados
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
WO2006116369A2 (en) * 2005-04-22 2006-11-02 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
AU2006244445B2 (en) * 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
ZA200709956B (en) * 2005-05-20 2009-02-25 Genentech Inc Pretreatment of a biological sample from an autoimmune disease subject
WO2006133450A2 (en) * 2005-06-08 2006-12-14 Duke University Anti-cd19 antibody therapy for the transplantation
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
BRPI0614183A2 (pt) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
JP2009502972A (ja) * 2005-07-29 2009-01-29 アムジエン・インコーポレーテツド タンパク質凝集を抑制する製剤
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1998799B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
JP5401314B2 (ja) 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008156494A1 (en) * 2006-11-03 2008-12-24 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
EP2097097B1 (en) * 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
WO2008098145A1 (en) * 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
US20090163698A1 (en) * 2007-05-11 2009-06-25 John Joseph Grigsby Method for Preparing Antibody Conjugates
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
WO2009054556A1 (en) * 2007-10-24 2009-04-30 Sang Yun Nam Method for preparation of therapeutic b cells against autoimmune diseases which are induced by autoimmune cytotoxicity
US9026372B2 (en) 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
WO2009105548A2 (en) * 2008-02-19 2009-08-27 Children's Medical Center Corporation Methods for treating diabetes
EP2257301B1 (en) 2008-03-03 2014-01-22 The University of Miami Allogeneic cancer cell-based immunotherapy
AU2009224690B2 (en) * 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
PL2262838T3 (pl) * 2008-03-13 2016-10-31 Środek do leczenia choroby
CN102027017A (zh) * 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
WO2010011697A1 (en) * 2008-07-21 2010-01-28 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
BRPI0919489A2 (pt) * 2008-09-29 2015-12-01 Biotest Ag composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
BR112012004777A2 (pt) 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
US20110070227A1 (en) * 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
GB0917054D0 (en) * 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN102586408B (zh) * 2011-01-12 2015-08-19 首都医科大学附属北京安贞医院 高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒
WO2012118750A2 (en) 2011-02-28 2012-09-07 Genentech, Inc. Biological markers and methods for predicting response to b-cell antagonists
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2734228A4 (en) 2011-07-18 2015-04-08 Ohio State Innovation Foundation FTY720 INCREASES CD74 RECEPTOR EXPRESSION AND SENSITIZES CANCER CELLS TO CELL DEATH INDUCED BY ANTI-CD74 ANTIBODIES
KR102117202B1 (ko) 2011-08-16 2020-06-01 모르포시스 아게 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2766482B1 (en) 2011-10-11 2016-12-07 The Brigham and Women's Hospital, Inc. Micrornas in neurodegenerative disorders
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
KR101482237B1 (ko) * 2012-05-11 2015-01-14 가톨릭대학교 산학협력단 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
JP2016513098A (ja) 2013-02-07 2016-05-12 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
EP2774930A1 (en) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016037985A1 (en) 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
SG11201707144VA (en) 2015-03-04 2017-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
AU2016353231B2 (en) 2015-11-13 2020-08-13 Dana-Farber Cancer Institute, Inc. An NKG2D-Ig fusion protein for cancer immunotherapy
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. EFFICACY OF ANTI-TROP-2 SN-38 ANTIBODY CONJUGATES FOR THE THERAPY OF REZIDIVATED / REFRACTORY TUMORS AGAINST CHECKPOINT INHIBITORS
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
CN108359004A (zh) * 2018-01-12 2018-08-03 中国农业科学院北京畜牧兽医研究所 犬重组干扰素-λ1及其制备方法与应用
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
CN115803010A (zh) 2020-07-09 2023-03-14 豪夫迈·罗氏有限公司 浓缩的蛋白质组合物、它们的制备及其用途
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen
CN113855792B (zh) * 2021-12-01 2022-03-01 上海惠盾因泰生物科技有限公司 重组hEGF-CRM197肿瘤治疗性疫苗配制剂
CN114778417B (zh) * 2022-04-29 2024-02-13 上海顿慧医疗科技发展有限公司 免疫检查点抑制剂相关不良反应风险预测的模型建立方法
CN119698305A (zh) 2022-08-10 2025-03-25 兴和株式会社 新药物复合体
CN115998903A (zh) * 2022-12-27 2023-04-25 浙江大学杭州国际科创中心 聚合物纳米颗粒在制备用于蛋白质降解的药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5340720A (en) * 1989-11-29 1994-08-23 University Of Kansas Methods of diagnosing and monitoring rheumatic diseases
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
WO1991013974A1 (en) * 1990-03-14 1991-09-19 The Biomembrane Institute Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US5679640A (en) * 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6863890B1 (en) * 1993-02-26 2005-03-08 Advanced Biotherapy, Inc. Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2240834C (en) * 1995-12-22 2013-12-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69831224T2 (de) * 1997-05-02 2006-03-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
EP1079862B1 (en) * 1998-05-20 2010-07-07 Immunomedics, Inc. Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
US6090335A (en) * 1999-01-08 2000-07-18 Northrop Grumman Corporation Process of forming fiber reinforced composite articles using an insitu cured resin infusion port
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
EP1645292A1 (en) * 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
JP4472351B2 (ja) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗ｃｄ７４抗体およびその使用方法
DE102004009617A1 (de) * 2004-02-27 2005-09-29 Siemens Ag Verfahren und Vorrichtung zur Codierung und Decodierung von strukturierten Dokumenten

Also Published As

Publication number Publication date
AU2005220212A1 (en) 2005-11-03
US20050191300A1 (en) 2005-09-01
AU2005220211A1 (en) 2005-11-03
CA2375912A1 (en) 2000-12-14
JP2003501401A (ja) 2003-01-14
JP4286483B2 (ja) 2009-07-01
KR20020020730A (ko) 2002-03-15
ES2331644T3 (es) 2010-01-12
HK1046635A1 (en) 2003-01-24
US20130071320A1 (en) 2013-03-21
CA2375912C (en) 2014-03-11
AU2005220212B2 (en) 2008-12-11
WO2000074718A1 (en) 2000-12-14
US20160039941A1 (en) 2016-02-11
ATE439860T1 (de) 2009-09-15
EP1194167B1 (en) 2009-08-19
US20110286918A1 (en) 2011-11-24
US20060051349A1 (en) 2006-03-09
DE05075555T1 (de) 2007-02-08
EP2289551A1 (en) 2011-03-02
US20110311531A1 (en) 2011-12-22
US20070020265A1 (en) 2007-01-25
DK1194167T3 (da) 2009-11-16
US20120114556A1 (en) 2012-05-10
AU2005220209B2 (en) 2008-11-27
HK1046635B (en) 2009-10-09
US7074403B1 (en) 2006-07-11
AU782160B2 (en) 2005-07-07
US7641901B2 (en) 2010-01-05
AU5600500A (en) 2000-12-28
EP1194167A1 (en) 2002-04-10
AU2005220209A1 (en) 2005-11-03
US20030133930A1 (en) 2003-07-17
CY1110556T1 (el) 2015-04-29
DE60042785D1 (de) 2009-10-01
AU2005220211B2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
CY1110556T1 (el) Ανοσοθεραπεια των αυτοανοσων διαταραχων χρησιμοποιωντας αντισωματα τα οποια στοχευουν τα β-κυτταρα
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
WO2002022212A8 (en) Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
EP0942959A4 (en) NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
WO2005056606A3 (en) Optimized antibodies that target the epidermal growth factor receptor
DE69638355D1 (de) Anti-CD3-Antikörper zur Verwendung zur Induzierung von Immunsuppression
EP0741748A4 (en) MONOCLONAL ANTIBODIES SPECIFIC TO VEGF RECEPTORS AND THEIR USE
PT1883698E (pt) Anticorpos monoclonais e fragmentos de anticorpo de cadeia única contra antigénio de membrana específico da próstata de superfície celular
NZ595450A (en) Antibodies to M-CSF
EP1808155A3 (en) Antibody-serum protein hybrids
DE60235588D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
EP1476120A4 (en) THERAPEUTIC METHODS USING ANTI-CD22 ANTIBODIES
SG156668A1 (en) Angiopoietin-2 specific binding agents
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2003013594A3 (en) Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation
WO2002076406A3 (en) Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
WO2005012351A3 (en) Novel functions for decay accelerating factor (daf) in inflammation
WO2003090675A3 (en) Methods and compositions useful for treating prostate cancer